Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Year A Pathway Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Perforating Fat Injections for Plantar Fasciosis

NCT02855983
View directory record Official record
Conditions
Plantar Fascia
Interventions
Fat Grafting
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 20, 2026, 2:30 PM EDT
Terminated Phase 3 Interventional Results available

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

NCT04931667
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Lorecivivint
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Tucson, Arizona • Winter Park, Florida • Oak Brook, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 20, 2026, 2:30 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fathers' Support Center New Pathways to Responsible Fatherhood Family Formation Program (NPFF) Impact Evaluation Plan

NCT03413709
View directory record Official record
Conditions
Parenting
Interventions
Family Formation Program
Other
Lead sponsor
Fathers' Support Center, St. Louis
Other
Eligibility
16 Years and older · Male only
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Autophagy Maintains Vascular Function Through a Novel Glycolysis-linked Pathway Regulating eNOS

NCT04200560
View directory record Official record
Conditions
Vascular Diseases
Interventions
Rhythmic Handgrip Exercise, Chronic Exercise Training
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

NCT02927769
View directory record Official record
Conditions
Hodgkin Disease
Interventions
Nivolumab, brentuximab vedotin, bendamustine
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 30 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 20, 2026, 2:30 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhancing Cancer Prevention and Control Pathways-Native Health Initiative

NCT04259762
View directory record Official record
Conditions
Cancer, Breast, Cancer, Colon, Cancer, Cervix
Interventions
Aim 8 (INT, Pilot Test): Breast, Colorectal, and Cervical Cancer Screening Cognitive-Behavioral Interventions
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
21 Years to 75 Years
Enrollment
508 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 20, 2026, 2:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Preparing for Prevention of Huntington's Disease (PREVENT-HD)

NCT04818060
View directory record Official record
Conditions
Huntington Disease
Interventions
Clinical Assessments, MRI Scan, Lumber Puncture (LP)
Other · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03213691
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm
Interventions
Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 20, 2026, 2:30 PM EDT
Recruiting Phase 2 Interventional

A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer

NCT06327490
View directory record Official record
Conditions
Breast Cancer
Interventions
ICG-guided manual lymphatic drainage, Traditional manual lymphatic drainage, Indocyanine green
Procedure · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

DAY101 In Gliomas and Other Tumors

NCT03429803
View directory record Official record
Conditions
Low-grade Glioma
Interventions
DAY101
Drug
Lead sponsor
Karen D. Wright, MD
Other
Eligibility
1 Year to 25 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 20, 2026, 2:30 PM EDT
Not listed No phase listed Observational

Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension

NCT04489251
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Protein Elisa analysis, microRNA analysis, whole exome sequencing
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

NCT01158300
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
VEGF inhibitor PTC299
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 20, 2026, 2:30 PM EDT
Active, not recruiting No phase listed Observational

Neuroblastoma Precision Trial

NCT02868268
View directory record Official record
Conditions
Neuroblastoma
Interventions
Gene panel sequencing of tumor specimens
Other
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Electronic Patient Reporting of Symptoms During Cancer Treatment

NCT03249090
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Patient Self-Reporting of Symptoms, Usual Care Delivery
Other
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
21 Years and older
Enrollment
1,197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
45
States / cities
Grand Junction, Colorado • Lawrenceville, Georgia • Harvey, Illinois + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 20, 2026, 2:30 PM EDT
Recruiting Phase 2 Interventional

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

NCT07223541
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

NCT03789175
View directory record Official record
Conditions
Cancer, Skin Fibroblasts, Muscle Weakness
Interventions
Nicotinamide Riboside (NR)
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Not applicable Interventional Results available

Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)

NCT05413239
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Psychoeducation to reduce diabetes distress and improve glycemic outcomes
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
14 Years to 25 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing a Novel Phototherapy Kiosk to Oral Vitamin D Supplementation

NCT04556136
View directory record Official record
Conditions
Hypovitaminosis D
Interventions
Standing Phototherapy Kiosk, D3 Oral supplement
Device · Dietary Supplement
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 69 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Progressive Brain Tumors

NCT00002944
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
carboplatin, lomustine, procarbazine hydrochloride, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 9 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
179
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 141 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Oct 20, 2026, 2:30 PM EDT
Recruiting Not applicable Interventional

Brief Motivational Interviewing +/- Mindfulness Training for Adolescent Alcohol Use in Pediatric Primary Care

NCT07059078
View directory record Official record
Conditions
Adolescent Alcohol Use
Interventions
Brief Motivational Interviewing-based Alcohol Intervention, Smartphone App-delivered Mindfulness Training
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 17 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Baltimore, Maryland • Belcamp, Maryland • Bowie, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 2:30 PM EDT
Recruiting Not applicable Interventional

Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway

NCT07175376
View directory record Official record
Conditions
Cancer, Frail, Chemotherapy
Interventions
Supportive Care
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 20, 2026, 2:30 PM EDT
Completed Not applicable Interventional

Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial

NCT04872413
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Biospecimen Collection, Follow-Up
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 20, 2026, 2:30 PM EDT
Terminated Phase 1 Interventional

Next Generation Personalized Neuroblastoma Therapy

NCT02780128
View directory record Official record
Conditions
Neuroblastoma, Cancer
Interventions
Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib
Procedure · Genetic · Other + 2 more
Lead sponsor
Yael P Mosse
Other
Eligibility
1 Year to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 20, 2026, 2:30 PM EDT